AndrewJCarterDO

PubMed

• Facility-based approach for the management of acute ST segment elevation myocardial infarction with cardiogenic shock in a rural medical centre: the Durango model.
  Andrew Joseph Carter, Jad Raffoul, Linden Lane, Leah LeSage, Shelley Langenhorst
  Open Heart. 2023-12-07
• 8 citations
  Drug-eluting stent fracture promise and performance.
  Andrew J. Carter
  Journal of the American College of Cardiology. 2009-11-17
• 155 citations
  Drug-Eluting Stents in Preclinical Studies Updated Consensus Recommendations for Preclinical Evaluation
  Robert S. Schwartz, Elazer R. Edelman, Renu Virmani, Andrew J. Carter, Juan F. Granada
  Circulation. Cardiovascular Interventions. 2008-10-01

Books/Book Chapters

• Textbook of Coronary Stenting 
  Chapter: Sirolimus Eluting Stent: Preclinical Studies. 
  Carter AJ, Kopia G, Falotico REditors: Stone GW and Leon MB.W. B. Saunders, Philadelphia, PA2007
• Handbook of Drug-eluting Stents. 
  Chapter: Histopathology of Restenosis. 
  Page 15 - 25Carter AJ, Tsao PEditors: Serruys PW and Girshlick A.Taylor and Francis, United Kingdom2005
• Handbook of Drug-eluting Stents. 
  Chapter: Sirolimus Eluting Stent: Preclinical Studies. 
  Page 93 - 103Carter AJ, Kopia G, Falotico REditors: Serruys PW and Girshlick A.Taylor and Francis, United Kingdom2005
• Handbook of Vulnerable Plaque 
  Chapter: Emerging Animal Models of Vulnerable Plaque. 
  Page 153 - 171Carter AJ, Wei WEditors: Serruys PW and Waksman R.Taylor and Francis, United Kingdom2004
• Drug Eluting Stent: Drug Eluting Stents in the Real World and the Clinical Results. 
  Chapter: Drug Eluting Stent Results in the Preclinical Studies. 
  Page 51 - 60Suzuki T, Carter AJMedical College Press, Japan2004
• Vascular Brachytherapy 
  Chapter: Lessons from the Feasibility Radioactive (IRIS) Stent Trials. 
  Page 441 - 451Fischell TA, Carter AJ, Foster M, Fischell RE, Fischell DREditors: Waksman R.Futura, NYEdition 3rd,2002
• Handbook of Coronary Stents 
  Chapter: Rapamycin Coated Stent. 
  Page 349 - 359Carter AJ, Falotico REditors: Serruys PW and Girshlick A.Martin Dunitz, The NetherlandsEdition 4th,2002
• Vascular Injury: Preclinical Studies. 
  Chapter: Atherosclerotic Porcine Coronary Stent Model: Technical Methods for Preclinical Studies. 
  Page 43 - 51Carter AJEditors: Simon DI and Rogers C.Humana Press Cardiology Series2001
• Vascular Brachytherapy 
  Chapter: Long-term effects of radioactive stents in experimental models. 
  Page 343 - 351Carter AJEditors: Waksman R.Futura, NYEdition 2nd,1999
• Vascular Brachytherapy 
  Chapter: Pathology of Radioactive Stents. 
  Page 353 - 363Virmani R, Carter AJ, Jones RM, Farb AEditors: Waksman R.Futura, NYEdition 2nd,1999
• Vascular Brachytherapy 
  Chapter: Lessons from the Feasibility Radioactive (IRIS) Stent Trials. 
  Page 475 - 481Fischell TA, Carter AJ, Foster M, Fischell RE, Fischell DREditors: Waksman R.Futura, NYEdition 2nd,1999
• Handbook of Vascular Brachytherapy. 
  Chapter: The Isostent Balloon Expandable Coronary Stent. 
  Page 59 - 67Fischell DR, Fischell TA, Fischell RE, Foster MT, Carter AJEditors: Waksman R, Serruys PW.Martin Dunitz, The Netherlands1998
• Handbook of Coronary Stents 
  Chapter: The Isostent Balloon Expandable Coronary Stent. 
  Page 213 - 219Fischell DR, Fischell TA, Fischell RE, Turnlund T, Carter AJEditors: Kutryk, M, Serruys PW.Martin Dunitz, The Netherlands1997
• Endoluminal Stenting 
  Chapter: Experimental observations with stents in canine and porcine coronary models. 
  Page 16 - 26Virmani R, Carter AJ, Farb A, Laird JR, Zidar JP, Stack RS, Reeves T, Yaklavich MEditors: Sigwart, U.WB Saunders, Philadelphia1996
• Vascular Brachytherapy 
  Chapter: A Beta Particle Emitting Radioisotope Stent for the Prevention of Restenosis. 
  Fischell TA, Laird JR, Carter AJ, Virmani R, Fischell DR, Fischell REEditors: Waksman, R, King SB, Crocker IR, Mould RF.Nucleotron, The NetherlandsEdition 1st,1996
• Join now to see all

Abstracts/Posters

• Clinical, Angiographic and IVUS Results from the Pivotal United States Spirit III Trial of the Xience™ V Everolimus Eluting Coronary Stent System in Patients with Coro...
  Stone G, Sood P, Midei M, Newman W, Sanz M, Hermiller J, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, Kereiakes D, Carter A, Williams D, Fortun..., Late Breaking Clinical Trial, American College of Cardiology Annual Scientific Session, New Orleans, LA, 3/24/2007
• Phramacokinetics and Pharmacodynamics of Stent-based Delivery of Sirolimus via a Novel Metallic Anisotropic Nanoporous Surface Coating.
  Carter AJ, Lye WK, Wamhoff B, Christians U, Tio F, Owens GK, Circulation, 1/1/2006
• In-vivo Performance of a Novel Co-polymer System for Extended Release of Zotarolimus in a Second Generation Drug-eluting Stent.
  Carter AJ, Melder R, Udipi K, Ozdil F, Virmani R, Wilcox JN, Am J Cardiol, 1/1/2006
• Increased Expression of eNOS by Endeavor, Zotarolimus Eluting Stents Compared to Other DES in Porcine Coronary Artery Implants.
  Haraguchi G, Pruitt S, Brodeur A, Collingwood R, Carter AJ, Melder R, Wilcox C, Am J Cardiol, 1/1/2006
• The Safety and Efficacy of Elective Percutaneous Coronary Intervention (PCI) Using Bivalirudin Versus Heparin and Glycoprotein IIbIIIa Inhibitors: Insight from the Blu...
  Gurm H, Smith D, Khanal S, Riba A, Carter AJ, LaLonde T, Kline-Rogers EM, Moscucci M, J Am Coll Cardiol, 1/1/2006
• The Effects of a Diffusion Barrier on the Elution Characteristics of ABT-578 via a Phosphorylcholine Matrix.
  Carter AJ, Brodeur A, Hasting E, Gibson L, Collingwood R, Ross S, Johnson M, Melder RJ, J Am Coll Cardiol, 1/1/2006
• Dose Response Effects of a Novel Slow-release Polymeric ABT-578 Eluting Stent.
  Carter AJ, Brodeur A, Hasting E, Gibson L, Collingwood R, Ross S, Caceres A, Jones R, Johnson M, Udipi K, Ozdil F, Melder RJ, Virmani R, Wilcox JN, Circulation, 1/1/2005
• Experimental Feasibility and Efficacy of a Novel Modular Segmented Stent with In-situ Programmable Length and Drug Elution from a Biodegradable Polymer Coating.
  Carter AJ, Gibson L, Haller S, Brodeur A, Collingwood R, Ross S, Marco P, Tio F, Robinson K, Am J Cardiol, 1/1/2005
• Comparative Efficacy of Everolimus and Sirolimus Delivered via Polymeric Drug Eluting Stents in the Porcine Coronary Model.
  Carter AJ, Wang CA, Royal J, Coleman L, Gibson L, Rossi A, Booth J, Jones R, Virmani R, J Am Coll Cardiol, 1/1/2004
• Similar Outcomes Between Patients with Native and Coronary Bypass Graft Disease Treated with Sirolimus Eluting Stents in the SECURE Trial.
  Costa M, Teirstein P, Leon MB, Bass T, Fischell T, Carter A, Yakubov S, J Am Coll Cardiol, 1/1/2004
• Initial Experience with Sirolimus Eluting Stents in Left Main no Option Patients: Data from the SECURE Trial.
  Yakubov S, Teirstein P, Leon MB, Bass T, Costa M, Carter AJ, Fischell T, J Am Coll Cardiol, 1/1/2004
• Sirolimus Eluting Stents for failed Brachytherapy: results from the SECURE Registry.
  Teirstein P, Bass TA, Costa MA, Yakubov S, Carter AJ, Moses JW, Leon MB, Mehran R, Price MJ, Fischell TA, J Am Coll Cardiol, 1/1/2004
• Intravascular Ultrasound Follow-up of the SECURE Trial: The Compassionate Use of Sirolimus Elutings Stents Study.
  Talwar K, Costa M, Teirstein P, Yakubov S, Carter AJ, Leon MB, Moses JW, Bass T, J Am Coll Cardiol, 1/1/2004
• Characterization of Neointimal Hyperplasia After Sirolimus Eluting Stent Implantation in Patients with Previous Brachytherapy Failure: Insights from the SECURE Study.
  Costa M, Talwar K, Panse N, Teirstein P, Yakubov S, Carter AJ, Bass T, Gilmore P, J Am Coll Cardiol, 1/1/2004
• Use of the Sirolimus-Eluting Bx Velocitytm Stent in Insulin Dependent Diabetics with Refractory Restenosis: Results from the SECURE Registry.
  Kao J, Teirstein PS, Moses JW, Leon MB, Yakubov S, Carter AJ, Circulation, 1/1/2004
• Sirolimus-Eluting Stent for the Treatment of Bypass Graft Disease; Long-term results of the Initial US Experience.
  Costa M, Gilmore P, Carter A, Teirstein P, Yakubov S, Sasseen B, Zenni M, Fischell T, Bass TA, Circulation, 1/1/2003
• Stents Coated with the Lipophilic Compound A24 Profoundly Inhibit Neointimal Formation in the Porcine Coronary Model.
  Carter AJ, Welch L, Gibson L, Sedlik S, Virmani R, J Am Coll Cardiol, 1/1/2003
• Sirolimus-Eluting Stent for the Treatment of Bypass Graft Disease: The Initial U. S. Experience.
  Costa M, Moses JW, Leon MB, Teirstein PS, Yakubov S, Carter AJ, Fischell TA, Bass TA, J Am Coll Cardiol, 1/1/2003
• Chronic Stent-Induced Injury and Inflammation results in Sustained Activation of the Cell Cycle in the Porcine Model.
  Aggarwal M, Tsao P, Kopia G, Glassford A, Yeung AC, Tio F, Carter AJ, J Am Coll Cardiol, 1/1/2003
• Use of the Sirolimus-Eluting Bx Velocity Stent for Failed Brachytherapy in Recurrent In-Stent Restenosis: Results from The Secure Registry.
  Teirstein PS, Kao J, Bass T, Costa MA, Yakubov S, Carter AJ, Moses JW, Leon MB, Fischell TA, J Am Coll Cardiol, 1/1/2003
• Experimental Evaluation of a Novel Balloon Expandable Stent and Delivery System for treatment of Coronary Bifurcation Lesions.
  Carter AJ, Ambrose D, Gibson L, Welch L, Coleman L, Virmani R, J Am Coll Cardiol, 1/1/2003
• Use of the Sirolimus-Eluting Bx Velocity Stent for Failed Brachytherapy in Recurrent In-Stent Restenosis: Results from The Secure Registry.
  Teirstein PS, Moses JW, Leon MB, Kao J, Bass TA, Costa MA, Yakubov S, Fischell TA, Carter AJ, Circulation, 1/1/2003
• Intravascular Ultrasound Follow-up of the SECURE Trial: The Compassionate Use of Sirolimus-Eluting Stent Study.
  Costa MA, Panse N, Teirstein P, Carter A, Yakubov S, Gilmore P, Zenni M, Sasseen B, Bass TA, Circulation, 1/1/2003
• Stent Based Delivery of Sirolimus is Associated with Increased Levels of p27kip1 Without Long-term Suppression of Neointimal Hyperplasia in the Porcine Model.
  Aggarwal M, Tsao P, Kopia G, Yeung AC, Tio F, Falotico R, Carter AJ, Circulation, 1/1/2002
• A Novel Inhibitor of Protein Kinase-C as a Therapeutic for Ischemic Reperfusion Injury in Acute Coronary Syndromes.
  Lee F, Inagaki K, Chen L, Bailey L, Ikeno F, Lyons J, Bouley D, Yock P, Carter A, Yeung A, Mochly-Rosen D, J Am Coll Cardiol, 1/1/2002
• Join now to see all

Lectures

• Specialized Stents for Specialized Situations. Drug Eluting Stents 2008. 
  3/31/2008
• New Polymeric Coatings. Emerging Technologies: Stents. 
  Chicago, IL - 3/29/2008
• Moderator, Novel Drug Eluting Stents. 
  Washington, DC - 10/21/2007
• Preclinical Evaluation of the Xtent Modular Segmented Drug Eluting Stent. 
  Barcelona, Spain - 5/25/2007
• Drug Eluting Stents for the Prevention of SFA Restenosis: Will this ever happen? 
  New Orleans, LA - 3/25/2007
• Pathology of Drug Eluting Stents. 
  New Orleans, LA - 3/25/2007
• Novel Stents. 
  New Orleans, LA - 3/25/2007
• Moderator, Update on Research, Development, and Regulatory Issues with Biodegradable Stents. 
  Washington, DC - 3/9/2007
• Bioabsorbable Stents: Basic Design Concepts. 
  Washington, DC - 3/9/2007
• Early and late effects of Polymers on the Vessel Wall. 
  Washington, DC - 3/9/2007
• Assessment of biological compatibility of polymers. 
  Geneva, Switzerland - 2/2/2007
• Coronary Vasomotor Function and DES: Insights into Mechanisms and Pathophysiology of Coronary Arterial Function with DES Formulations in Experimental Models. 
  Geneva, Switzerland - 2/2/2007
• Co-chairman, From bench to clinics: Models to assess vascular healing response: from wound healing to vascular re-endothelialization. 
  Geneva, Switzerland - 2/2/2007
• Rationale for Combination Drug-eluting Stents: Advantages and Pitfalls. 
  Washington, DC - 10/26/2006
• Early and Late Effects of Durable and Biosorbable Polymers on the Vessel Wall. DES Next Generation Basic Science Workshop. 
  Washington, DC - 10/24/2006
• Comparative Experimental Findings of Polymers and Drugs: Are there differences between the current drug eluting stents in clinical use and investigation? DES Next Gene... 
  Washington, DC - 10/23/2006
• Symposium co-chairman, DES Next Generation Basic Science Workshop. 
  Washington, DC - 10/23/2006
• Have you seen a bifurcation lesion? Perspectives from an anatomopatholgist. 
  Rome, Italy - 9/26/2006
• Moderator, Complications of Drug Eluting Stents: Late Stent Thrombosis. 
  Singapore - 2/27/2006
• DES Spirit of XIENCE stent. 
  Singapore - 2/27/2006
• Cell Recruitment for Stent Reendothelialization: Experimental Data for the anti-CD34 Stent. 
  Geneva, Switzerland - 2/3/2006
• Prevention of Restenosis: DES with Semisynthetic or Novel Polymers: Experimental Data. 
  Geneva, Switzerland - 2/3/2006
• Polymer Interactions with the Vessel Wall. 
  Washington, DC - 10/17/2005
• Non-polymeric Methods for Stent-based Drug Delivery. 
  Washington, DC - 10/17/2005
• Drug-eluting Stents: "Next Generation" Basic Science Workshop, Symposium Co-chairman 
  Washington, DC - 10/17/2005
• Join now to see all

Other

• Methods and Kits for Locally Administering an Active Agent to an Interstitial Space of a Host 
  Carter A, U.S. Patent No. 6,346,098
• Anti-inflammatory Drug and Delivery Device 
  Carter A, U.S. Patent No. 6,776,796
• Drug/Drug Delivery Systems for the Prevention and Treatment of Vascular Disease 
  Carter A, U.S. Patent No. 8236048 B2